Billionaire investor Stanley Druckenmiller is known for making bold moves when conviction is high, and his latest portfolio changes suggest he sees a major opportunity developing in one corner of the market.
During the most recent quarter, Druckenmiller aggressively added to one large-cap tech position while reducing exposure to two major healthcare holdings that remain among his biggest investments.
Here’s what Druckenmiller is buying, what he is trimming, and what those moves may signal for investors.
Alphabet Is Druckenmiller’s Big New Bet
The most aggressive move Druckenmiller made last quarter was a 276.7% increase in Alphabet (NASDAQ:GOOGL | GOOGL Price Prediction), bringing the position to approximately $120.5 million, or 2.8% of the portfolio. The move suggests Druckenmiller sees growing opportunity as Alphabet’s business momentum accelerates.
Google Cloud revenue grew 48% in Q4 2025 to $17.66 billion, while segment operating income more than doubled. For the full year, Alphabet generated $132.17 billion in net income, up 32%, as revenue topped $400 billion for the first time.
Management is now leaning heavily into AI infrastructure, guiding for $175 billion to $185 billion in 2026 capital expenditures, nearly double FY2025 levels. CEO Sundar Pichai recently said the company’s AI investments are “driving revenue and growth across the board,” while the Gemini app has already reached 750 million monthly active users.
Alphabet shares have climbed 108.31% over the past year, yet Druckenmiller’s buying suggests he still sees upside ahead in one of the market’s dominant AI infrastructure plays.
Natera Remains Duquesne’s Largest Holding Despite the Trim
Despite trimming the position by 21.9% during the quarter, Natera (NASDAQ:NTRA) remains Druckenmiller’s largest disclosed holding by a wide margin. He still owns 2,511,357 shares valued at roughly $575.3 million, representing 13.38% of his portfolio. Keeping Natera as his top position suggests the trim was more likely portfolio management than a sign of fading conviction.
The company’s core thesis remains intact. Natera’s Signatera oncology test delivered approximately 225,000 clinical MRD volumes in Q4 2025, up 56% year over year, reflecting continued adoption of its cancer diagnostics platform.
While shares have fallen 15.74% year to date, Druckenmiller’s willingness to maintain Natera as his largest holding suggests he still sees substantial long-term upside in the oncology diagnostics story.
Insmed Gets Trimmed but Conviction Remains Strong
Druckenmiller also reduced his stake in Insmed (NASDAQ:INSM) by 38.86% during the quarter, though the biotech remains one of his largest positions. The firm still holds roughly $257.9 million worth of shares, equal to 6% of the portfolio, making it Druckenmiller’s third-largest disclosed holding.
Insmed’s investment thesis centers around BRINSUPRI, the first and only approved treatment for non-cystic fibrosis bronchiectasis. The drug generated $144.6 million in Q1 2026 during its first full commercial quarter, helping total company revenue surge 152.6% year over year to $263.84 million.
Management now expects BRINSUPRI to generate at least $1 billion in revenue in 2026, with long-term peak sales potential exceeding $5 billion.
While the company posted a wider-than-expected Q1 loss as launch investments ramped, Druckenmiller’s sizable remaining position suggests he still believes Insmed could become a major long-term winner if BRINSUPRI continues gaining traction.
